이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

패혈증의 면역 기능 장애 평가

2026년 9월 21일 업데이트: University of Minnesota

Sepsis leads to sustained immune system dysfunction resulting in increased susceptibility to secondary infection while in the hospital or after discharge. Consequently, many of the ~2 million Americans that develop sepsis every year will end up back in the ICU, weeks and months later. The objective of this study is to define the cellular and molecular mechanisms driving the dysfunction and reprogramming of T cells and B cells that mediate cellular and humoral immunity using a combination of phenotypic, functional, genomic, and metabolomic assays.

연구 개요

상태

모병

정황

연구 유형

관찰

등록 (추정된)

150

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Mrunmayi Tilak
  • 전화번호: 612-624-9990
  • 이메일: mtilak@umn.edu

연구 장소

    • Minnesota
      • Minneapolis, Minnesota, 미국, 55455
        • 모병
        • University of Minnesota
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Patients with and without sepsis in the ICU, compared to healthy volunteers

설명

ICU With Sepsis Inclusion Criteria:

  • Age ≥ 18

  • Presumed diagnosis of sepsis, defined as "patients with life-threatening organ dysfunction caused by a dysregulated host response to infection"

  • Patients in the ICU who meet 2 or more of the quick SOFA (qSOFA) definition along with organ dysfunction:

    1. Respiration rate ≥ 22 breaths/min and/or mechanically ventilated
    2. An alteration in mental status
    3. Systolic blood pressure of less than 100 mm Hg and/or receiving inotropes to maintain blood pressure AND/OR
    1. An acute change in SOFA score ≥2 points, consequent to the infection (can assume SOFA score = 0 in patients with no pre-existing organ dysfunction)

ICU Without Sepsis Inclusion Criteria:

  • Age ≥ 18
  • Patients requiring care at a M Health Fairview ICU due to high acuity of illness and no other evidence of sepsis

Healthy Volunteer Inclusion Criteria

  • Age greater or equal to 18
  • ASA status 1, 2 or 3
  • May include patients who are receiving dialysis in an outpatient setting

Exclusion Criteria (all groups):

  • Active cancer with chemotherapy and/or radiation treatment within the past 6 weeks
  • Medication usage that includes immunosuppressive drugs, biologic agents, cytokines, growth factor and interleukins
  • Steroid medication usage of > 300mg hydrocortisone per day (equivalent of > 20mg prednisone). Patients with chronic steroid use will be excluded, however patients who have had stress dose steroids administered following admission will be included.
  • Patients with a history of, or who currently have evidence of autoimmune disease, including but not limited to: myasthenia gravis, Guillain Barré syndrome, systemic lupus erythematosus, multiple sclerosis, scleroderma, ulcerative colitis, Crohn's disease, autoimmune hepatitis, Wegener's granulomatosis, HIV/AIDS, etc.
  • Patients with active or a history of acute or chronic lymphocytic leukemia
  • Known history of chronic hepatitis B (HBV) infection and not on treatment with HBV nucleoside analogues prior to the current hospitalization, or HBV DNA > 100 IU/mL
  • Known history of infection with hepatitis C (HCV) and currently undergoing treatment for HCV infection or has detectable HCV RNA
  • Participation in another investigational interventional drug study within the past 4 weeks
  • Current pregnancy
  • Current incarceration

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: CASE_CONTROL
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
건강한 자원봉사자

No intervention is included in this study

패혈증이있는 ICU 환자

No intervention is included in this study

패혈증이없는 ICU 환자

No intervention is included in this study

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
EliSpot - Day 1
기간: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
EliSpot - Day 4
기간: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
EliSpot - Day 7
기간: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
EliSpot - Day 14
기간: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
EliSpot - Day 21
기간: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
EliSpot - Day 28
기간: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Ex Vivo TNF Production - Day 1
기간: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Ex Vivo TNF Production - Day 4
기간: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Ex Vivo TNF Production - Day 7
기간: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Ex Vivo TNF Production - Day 14
기간: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Ex Vivo TNF Production - Day 21
기간: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Ex Vivo TNF Production - Day 28
기간: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Flow Cytometry of Peripheral Blood Leukocytes - Day 1
기간: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Flow Cytometry of Peripheral Blood Leukocytes - Day 4
기간: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Flow Cytometry of Peripheral Blood Leukocytes - Day 7
기간: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Flow Cytometry of Peripheral Blood Leukocytes - Day 14
기간: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Flow Cytometry of Peripheral Blood Leukocytes - Day 21
기간: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Flow Cytometry of Peripheral Blood Leukocytes - Day 28
기간: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Quantification of Cytokines in Serum - Day 1
기간: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Quantification of Cytokines in Serum - Day 4
기간: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Quantification of Cytokines in Serum - Day 7
기간: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Quantification of Cytokines in Serum - Day 14
기간: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Quantification of Cytokines in Serum - Day 21
기간: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Quantification of Cytokines in Serum - Day 28
기간: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Quantification of Chemokines in Serum - Day 1
기간: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Quantification of Chemokines in Serum - Day 4
기간: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Quantification of Chemokines in Serum - Day 7
기간: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Quantification of Chemokines in Serum - Day 14
기간: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Quantification of Chemokines in Serum - Day 21
기간: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Quantification of Chemokines in Serum - Day 28
기간: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Transcriptional Profiling - Day 1
기간: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Transcriptional Profiling - Day 4
기간: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Transcriptional Profiling - Day 7
기간: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Transcriptional Profiling - Day 14
기간: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Transcriptional Profiling - Day 21
기간: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Transcriptional Profiling - Day 28
기간: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
CBC - Day 1
기간: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
CBC - Day 4
기간: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
CBC - Day 7
기간: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
CBC - Day 14
기간: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
CBC - Day 21
기간: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
CBC - Day 28
기간: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Thomas Griffith, PhD, University of Minnesota

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 3월 1일

기본 완료 (추정된)

2028년 11월 1일

연구 완료 (추정된)

2028년 11월 1일

연구 등록 날짜

최초 제출

2025년 8월 26일

QC 기준을 충족하는 최초 제출

2025년 8월 26일

처음 게시됨 (실제)

2025년 9월 4일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 23일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 21일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • URO-2025-34202

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다